U.S. Markets
Johnson & Johnson (JNJ) entered strategic agreements with Sail Biomedicines, winning an exclusive option to acquire the company for USD 2.58bln, along with an equity investment and total initial payments of USD 785mln, according to SEC filing
StockNow breaking-news AI analysis
JNJ entered a strategic agreement with Sail Biomedicines, including a $785M initial investment and an exclusive $2.58B acquisition option, according to an SEC filing reported on July 29, 2026.
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
